Retained Earnings (Accumulated Deficit) of Can-Fite BioPharma Ltd. from 31 Dec 2018 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Can-Fite BioPharma Ltd. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2018 to 30 Jun 2025.
  • Can-Fite BioPharma Ltd. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Jun 2025 was $171,237,000, a 5.4% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Can-Fite BioPharma Ltd. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $171,237,000 -$8,799,000 -5.4% 30 Jun 2025 6-K 28 Aug 2025 2025 Q2
Q4 2024 $166,361,000 -$7,880,000 -5% 31 Dec 2024 6-K 28 Aug 2025 2025 Q2
Q2 2024 $162,438,000 -$7,371,000 -4.8% 30 Jun 2024 6-K 29 Aug 2024 2024 Q2
Q4 2023 $158,481,000 -$7,634,000 -5.1% 31 Dec 2023 20-F 14 Apr 2025 2024 FY
Q2 2023 $155,067,000 -$9,768,000 -6.7% 30 Jun 2023 6-K 31 Aug 2023 2023 Q2
Q4 2022 $150,847,000 -$10,173,000 -7.2% 31 Dec 2022 20-F 28 Mar 2024 2023 FY
Q2 2022 $145,299,000 -$14,733,000 -11% 30 Jun 2022 6-K 25 Aug 2022 2022 Q2
Q4 2021 $140,674,000 -$15,205,000 -12% 31 Dec 2021 20-F 30 Mar 2023 2022 FY
Q2 2021 $130,566,000 -$11,305,000 -9.5% 30 Jun 2021 6-K 26 Aug 2021 2021 Q2
Q4 2020 $125,469,000 -$15,158,000 -14% 31 Dec 2020 20-F 24 Mar 2022 2021 FY
Q2 2020 $119,261,000 30 Jun 2020 6-K 27 Aug 2020 2020 Q2
Q4 2019 $110,311,000 -$12,625,000 -13% 31 Dec 2019 20-F 25 Mar 2021 2020 FY
Q4 2018 $97,686,000 31 Dec 2018 6-K 01 Jun 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.